Onivyde Too Expensive For NICE, Despite Dearth Of Pancreatic Cancer Drugs

NICE has not recommended Shire's Onivyde in draft guidance as it is not cost effective, the HTA body for England and Wales said. The pancreatic cancer treatment has also struggled to make its mark on the US market where it is being commercialized by Merrimack Pharmaceuticals.